3 papers in the library · 36 citations · publishing 2022-2025
Psychopharmacology March 2, 2022 Piotr Popik, Adam S. Hogendorf, Ryszard Bugno et al. 30 citations
Time underestimation caused by (S)-ketamine may be linked to its antidepressant effects, but this came with severe behavioral disruption. The authors propose that behavioral disruption induced by psychedelics objectively indicates their psychotomimetic-like actions.
Journal of Psychopharmacology October 16, 2023 Maciej Koniewski, Piotr Popik, Natalia Malikowska‐racia et al. 6 citations
Psilocybin, but not LSD, produced an immediate antidepressant-like effect in rats tested on a differential reinforcement of low-rate responding (DRL 72s) schedule, shown by increased reinforced presses and response efficiency. Neither drug showed lasting effects up to four weeks after administration. The DRL 72s test, which reliably distinguishes antidepressants from other psychoactive drugs, detected only acute changes. These results suggest that detecting sustained antidepressant-like effects in rodents may require new behavioral methods, and question whether prolonged efficacy observed in humans depends on the psychotherapy typically paired with psychedelic treatment.
Journal of psychopharmacology (Oxford, England) December 26, 2025 Natalia Malikowska-Racia, Joanna Gołębiowska, Katarzyna Starowicz et al.
Ketamine isoforms (R-, S-, and racemic R,S-) do not produce opioid- or cannabis-like subjective effects and are unlikely to fully mask the interoceptive effects of morphine or THC. In rats trained to discriminate morphine or THC from vehicle, none of the ketamine isoforms fully blocked the discriminative stimulus effects of morphine or THC, nor did they fully substitute for either drug. Ketamine isoforms did not alter response rates in the morphine experiment but suppressed responding in the THC experiment, suggesting coadministration with cannabinoids may lead to pronounced sedative-like suppression. These findings warrant further investigation into the safety and interaction profiles of such drug combinations.